{"classes":[{"categories":[{"measurements":[{"comment":"The median OS time is the time point (from transplant) at which the probability of survival is 50%. If you look at the KM curve below for OS, the curve is going down overtime but has not reached the horizontal line for probability=0.5. The median OS time has not been reached. The 95% CI is not estimable.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Estimated using the Kaplan-Meier method. Cox proportional hazards model will be used to include multiple covariates. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Lenalidomide)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"through out study treatment and up to 30 days after completion of study treatment, up to 119 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}